60 related articles for article (PubMed ID: 35138335)
1. Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma.
Reijers ILM; Rawson RV; Colebatch AJ; Rozeman EA; Menzies AM; van Akkooi ACJ; Shannon KF; Wouters MW; Saw RPM; van Houdt WJ; Zuur CL; Nieweg OE; Ch'ng S; Klop WMC; Spillane AJ; Long GV; Scolyer RA; van de Wiel BA; Blank CU
JAMA Surg; 2022 Apr; 157(4):335-342. PubMed ID: 35138335
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant in Situ and Systemic Immunotherapy with Lymph Node Cryoablation in Resectable Stage III Melanoma Metastasis: a Proof-of-Concept Study.
Braud A; Auloge P; Meyer N; Bouvrais C; Gharbi M; Lang H; Gangi A; Lipsker D
Cardiovasc Intervent Radiol; 2024 May; 47(5):567-572. PubMed ID: 38570342
[TBL] [Abstract][Full Text] [Related]
3. Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease.
Diem S; Hasan Ali O; Ackermann CJ; Bomze D; Koelzer VH; Jochum W; Speiser DE; Mertz KD; Flatz L
Cancer Immunol Immunother; 2018 Jan; 67(1):39-45. PubMed ID: 28894934
[TBL] [Abstract][Full Text] [Related]
4. Case report: Durable complete response of a mucosal melanoma of the rectum after neoadjuvant immunotherapy with ipilimumab plus nivolumab.
Krueger O; Eisenburger R; Tasdogan A; Zimmer L; Livingstone E; Hadaschik E; Theurer S; Brodin B; Schadendorf D; Ugurel S
Front Immunol; 2024; 15():1369190. PubMed ID: 38807589
[TBL] [Abstract][Full Text] [Related]
5. Ipilimumab and Radiation in Patients with High-risk Resected or Regionally Advanced Melanoma.
Salama AKS; Palta M; Rushing CN; Selim MA; Linney KN; Czito BG; Yoo DS; Hanks BA; Beasley GM; Mosca PJ; Dumbauld C; Steadman KN; Yi JS; Weinhold KJ; Tyler DS; Lee WT; Brizel DM
Clin Cancer Res; 2021 Mar; 27(5):1287-1295. PubMed ID: 33172894
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.
Blank CU; Lucas MW; Scolyer RA; van de Wiel BA; Menzies AM; Lopez-Yurda M; Hoeijmakers LL; Saw RPM; Lijnsvelt JM; Maher NG; Pulleman SM; Gonzalez M; Torres Acosta A; van Houdt WJ; Lo SN; Kuijpers AMJ; Spillane A; Klop WMC; Pennington TE; Zuur CL; Shannon KF; Seinstra BA; Rawson RV; Haanen JBAG; Ch'ng S; Naipal KAT; Stretch J; van Thienen JV; Rtshiladze MA; Wilgenhof S; Kapoor R; Meerveld-Eggink A; Grijpink-Ongering LG; van Akkooi ACJ; Reijers ILM; Gyorki DE; Grünhagen DJ; Speetjens FM; Vliek SB; Placzke J; Spain L; Stassen RC; Amini-Adle M; Lebbé C; Faries MB; Robert C; Ascierto PA; van Rijn R; van den Berkmortel FWPJ; Piersma D; van der Westhuizen A; Vreugdenhil G; Aarts MJB; Stevense-den Boer MAM; Atkinson V; Khattak M; Andrews MC; van den Eertwegh AJM; Boers-Sonderen MJ; Hospers GAP; Carlino MS; de Groot JB; Kapiteijn E; Suijkerbuijk KPM; Rutkowski P; Sandhu S; van der Veldt AAM; Long GV
N Engl J Med; 2024 Jun; ():. PubMed ID: 38828984
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Stage III Resectable Melanoma-Adjuvant and Neoadjuvant Approaches.
Tarhini AA; Castellano E; Eljilany I
Cancer J; 2024 Mar-Apr 01; 30(2):54-70. PubMed ID: 38527258
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant Immune Checkpoint Inhibition in Metastatic Conjunctival Melanoma.
Fan K; Waninger JJ; Yentz S; McLean S; Demirci H
Ophthalmic Plast Reconstr Surg; 2023 Sep-Oct 01; 39(5):e152-e155. PubMed ID: 37207285
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant ipilimumab plus nivolumab therapy as a potential organ preservation strategy in mucosal melanoma: case report.
Ong CV; Samlowski W
Front Oncol; 2024; 14():1301424. PubMed ID: 38549929
[TBL] [Abstract][Full Text] [Related]
10. Plain language summary of the CheckMate 76K study results: nivolumab given after stage 2B/2C melanoma is removed by surgery.
Kirkwood JM; Vecchio MD; Weber J; Hoeller C; Grob JJ; Mohr P; Loquai C; Dutriaux C; Chiarion-Sileni V; Mackiewicz J; Rutkowski P; Arenberger P; Quereux G; Meniawy TM; Ascierto PA; Menzies AM; Durani P; Lobo M; Campigotto F; Gastman B; Long GV
Future Oncol; 2024 May; 20(15):959-968. PubMed ID: 38390818
[TBL] [Abstract][Full Text] [Related]
11. Neo-Adjuvant Therapy for Metastatic Melanoma.
Kuijpers AMJ; van Akkooi ACJ
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38610925
[TBL] [Abstract][Full Text] [Related]
12. Association between pathologic response and survival after neoadjuvant therapy in lung cancer.
Deutsch JS; Cimino-Mathews A; Thompson E; Provencio M; Forde PM; Spicer J; Girard N; Wang D; Anders RA; Gabrielson E; Illei P; Jedrych J; Danilova L; Sunshine J; Kerr KM; Tran M; Bushong J; Cai J; Devas V; Neely J; Balli D; Cottrell TR; Baras AS; Taube JM
Nat Med; 2024 Jan; 30(1):218-228. PubMed ID: 37903504
[TBL] [Abstract][Full Text] [Related]
13. A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma.
Roland CL; Nassif Haddad EF; Keung EZ; Wang WL; Lazar AJ; Lin H; Chelvanambi M; Parra ER; Wani K; Guadagnolo BA; Bishop AJ; Burton EM; Hunt KK; Torres KE; Feig BW; Scally CP; Lewis VO; Bird JE; Ratan R; Araujo D; Zarzour MA; Patel S; Benjamin R; Conley AP; Livingston JA; Ravi V; Tawbi HA; Lin PP; Moon BS; Satcher RL; Mujtaba B; Witt RG; Traweek RS; Cope B; Lazcano R; Wu CC; Zhou X; Mohammad MM; Chu RA; Zhang J; Damania A; Sahasrabhojane P; Tate T; Callahan K; Nguyen S; Ingram D; Morey R; Crosby S; Mathew G; Duncan S; Lima CF; Blay JY; Fridman WH; Shaw K; Wistuba I; Futreal A; Ajami N; Wargo JA; Somaiah N
Nat Cancer; 2024 Apr; 5(4):625-641. PubMed ID: 38351182
[TBL] [Abstract][Full Text] [Related]
14. The Effect of Neoadjuvant Systemic Therapy on Surgical Outcomes After Lymph Node Dissections for Stage III Melanoma; An Australian Cohort.
Zijlker LP; Chen H; Spillane AJ; Gonzalez M; Pennington TE; Menzies AM; Lo SN; Ferguson P; Rawson R; Colebatch AJ; Stretch JR; Thompson JF; Ch'ng S; Nieweg O; Shannon KF; Long GV; Scolyer RA; Saw RPM; van Akkooi ACJ
Ann Surg Oncol; 2024 May; ():. PubMed ID: 38762644
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant immune checkpoint inhibitor therapy may benefit pediatric patients with stage III melanoma and sentinel lymph node positivity: a case series.
Bowden A; Zambito J; El-Feghaly J; Andolina JR
Pediatr Hematol Oncol; 2024 May; ():1-10. PubMed ID: 38712383
[TBL] [Abstract][Full Text] [Related]
16. Different pathologic responses to neoadjuvant anti-PD-1 in primary squamous lung cancer and regional lymph nodes.
Ling Y; Li N; Li L; Guo C; Wei J; Yuan P; Tan F; Tao X; Wang S; Wang Z; Wu N; Wang J; Ying J; Gao S; He J
NPJ Precis Oncol; 2020 Dec; 4(1):32. PubMed ID: 33299121
[TBL] [Abstract][Full Text] [Related]
17. Optimal Practices for Suspected Nodal Melanoma-The Role of the General Surgeon.
Rog CJ; Puzanov I; Skitzki J
JAMA Surg; 2024 Apr; 159(4):361-362. PubMed ID: 38416463
[TBL] [Abstract][Full Text] [Related]
18. Gut microbiome is associated with recurrence-free survival in patients with resected Stage IIIB-D or Stage IV melanoma treated with immune checkpoint inhibitors.
Usyk M; Hayes RB; Knight R; Gonzalez A; Li H; Osman I; Weber JS; Ahn J
bioRxiv; 2024 Apr; ():. PubMed ID: 38659744
[TBL] [Abstract][Full Text] [Related]
19. ASO Visual Abstract: The Effect of Neoadjuvant Systemic Therapy on Surgical Outcomes After Lymph Node Dissections for Stage III Melanoma: An Australian Cohort.
Zijlker LP; Chen H; Spillane AJ; Gonzalez M; Pennington TE; Menzies AM; Lo SN; Ferguson P; Rawson R; Colebatch AJ; Stretch JR; Thompson JF; Ch'ng S; Nieweg O; Shannon KF; Long GV; Scolyer RA; Saw RPM; van Akkooi ACJ
Ann Surg Oncol; 2024 May; ():. PubMed ID: 38758487
[No Abstract] [Full Text] [Related]
20. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial.
Reijers ILM; Menzies AM; van Akkooi ACJ; Versluis JM; van den Heuvel NMJ; Saw RPM; Pennington TE; Kapiteijn E; van der Veldt AAM; Suijkerbuijk KPM; Hospers GAP; Rozeman EA; Klop WMC; van Houdt WJ; Sikorska K; van der Hage JA; Grünhagen DJ; Wouters MW; Witkamp AJ; Zuur CL; Lijnsvelt JM; Torres Acosta A; Grijpink-Ongering LG; Gonzalez M; Jóźwiak K; Bierman C; Shannon KF; Ch'ng S; Colebatch AJ; Spillane AJ; Haanen JBAG; Rawson RV; van de Wiel BA; van de Poll-Franse LV; Scolyer RA; Boekhout AH; Long GV; Blank CU
Nat Med; 2022 Jun; 28(6):1178-1188. PubMed ID: 35661157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
